Potential Contamination Leads to Recall of VistaPharm’s Sucralfate
In patients who are immunocompromised, Bacillus cereus can result in life-threatening infections such as endocarditis and necrotizing soft tissue infections.
VistaPharm is recalling one lot of Sucralfate Oral Suspension, 1g/10mL, which is used to treat patients with duodenal ulcers, because of Bacillus cereus contamination in the product. Bacillus cereus is a Gram-positive bacteria found in food and cause food poisoning. But in patients who are immunocompromised, Bacillus cereus can result in life-threatening infections such as endocarditis and necrotizing soft tissue infections.
VistaPharm has not received any reports of adverse events. A contractor, Inmar, is conducting the recall.
The affected lot, 810300, has an expiration date of Oct. 31, 2023, and NDC number 66689-305-16.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
